Short answer
Humacyte, Inc. (HUMA) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $753,000 with net income of −$18M.
Q3 2025 key financials · XBRL
- Revenue
- $753,000
- +150.2% QoQ
- Net income
- −$18M
- +55.3% YoY · +53.5% QoQ
- Operating margin
- -3239.0%
- EPS (diluted)
- −$0.12
- +62.5% YoY · +55.6% QoQ
Source: XBRL data from the Humacyte, Inc. (HUMA) Q3 2025 10-Q on SEC EDGAR. USD.
Humacyte, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $0.8M vs $0, comprising $0.7M Symvess product sales and $0.1M contract revenue
- Q3 operating loss $24.4M vs $30.2M; operating margin -3,240.6% vs not meaningful with zero prior-year revenue
- Best R&D segment AV Access, $1.6M vs $1.9M; worst PAD, $0 vs $22K
- Nine-month operating cash flow use $78.9M vs $71.5M; cash $19.5M plus restricted cash $0.4M
- Outlook: operating losses and negative cash flows expected; cash and stock-purchase capacity fund operations at least 12 months
Risk Factors
- Newly added cost-saving risk triggered by April 28, 2025 workforce reduction of 30 employees
- Most materially updated risk: cost reductions may produce lower-than-forecast savings and higher-than-forecast charges
- Operational risk: additional employee attrition could reduce productivity through lost knowledge and transitional inefficiencies
- Financial risk: severance costs from headcount reductions could negatively affect cash flows
- Compliance and regulatory risks: no material changes reported from the 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Humacyte, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.